// App-Quantinova.ai

P3-10-17 : CREBBP alterations lead to CDK4/6 inhibitor sensitivity in triple negative breast cancer

Researchers

Presenter

  • Rachael Natrajan

Principal Investigators

  • N/A

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Solid malignancies

  • Lymphomas

Biomarkers

  • CREB-binding protein

  • Cyclin-dependent kinase 4

  • Forkhead box M1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved